Why this is an Awesome Time to Buy Axsome Therapeutics

Monday, March 1, 2021 | MarketBeat Staff
Why this is an Awesome Time to Buy Axsome Therapeutics

The biotechnology space is about as risky as it gets when it comes to industry groups. The hard to predict nature of clinical trials can make for some dramatic swings in stock prices.

Investors that have the risk tolerance (and stomach) to venture into biotech have to weigh the risks and rewards of these companies. One name that appears to be well worth the risk is biopharmaceutical mid-cap Axsome Therapeutics (NASDAQ:AXSM).

 What is the Focus of Axsome Therapeutics?

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders. It has several candidates in its pipeline for major depressive disorder (MDD), treatment-resistant depression (TRD), and agitation related to Alzheimer's disease (AD).

Its most promising product candidate is AXS-05 which is being evaluated for multiple indications. Axsome plans to submit a new drug application (NDA) to the U.S. Food & Drug Administration (FDA) for AXS-05 in MDD as soon as this month.

The novel AXS-05 oral treatment is also being studied as a possible treatment for Alzheimer's disease agitation. In June 2020, the FDA granted the Breakthrough Therapy designation for AXS-05 in AD agitation. The designation is said to put a drug candidate on the fast track towards potential approval.

The company's lead candidate is also part of a study involving patients with MDD and suicidal ideation. Positive results from Phase 2 of that study were recently announced.

Back in January, Axsome's migraine drug, AXS-07, demonstrated positive long-term safety data in a study of patients who suffer from migraine attacks. The data showed an ability to provide migraine pain relief and had a favorable safety profile. Out of the 706 patients enrolled in the study, two-thirds were pain-free two hours after receiving AXS-07. An NDA for this product candidate is also expected to be filed this quarter.

What are Axsome Therapeutics' Market Opportunities?

So, while Axsome's development pipeline is clearly impressive, how does this translate to its potential financial performance? The global market for MDD alone is estimated to be more than $9 billion. Its this opportunity that the market took notice of after Axsome reported positive efficacy and safety data from its Phase 3 study. It was also the reason the stock gapped significantly higher in six-times its average trading volume in April 2020.

The potential windfall from AXS-05 is expanded by the candidate's potential use with Alzheimer's agitation which the company estimates to be a $3 billion global market. AXS-05 is also being evaluated as a possible cessation product for cigarette smokers. If approved for this purpose, it would tack on another $4 billion to Axsome's market opportunity.

The opportunity in the migraine market is not as big as that of MDD but is still substantial considering approximately 1 billion people worldwide will suffer from migraines this year. At an estimated $1.5 billion to $2.0 billion, the global migraine market represents a diversifying growth avenue for Axsome that surely any biotech company its size would welcome.

The huge revenue opportunities don't end there. Axsome's narcolepsy drug, AXS-12, is also in a pivotal clinical trial. Narcolespy, which is becoming an increasingly prevalent issue globally, is expected to become a $5 billion market within the next five years.

Last but not least, is AXS-14, Axsome's fibromyalgia therapy which it actually acquired from Pfizer years ago for $11 million. Pfizer chose not to move forward with the drug, but considering it showed positive data in a Phase 3 study at Pfizer, it could be yet another product to generate revenue for Axsome.

 Is Axsome Therapeutics Stock a Buy?

A little over two years ago Axsome Therapeutics stock traded below $2 only to skyrocket above $100 in April of last year. The stock has since trended lower largely due to concerns that the pandemic will push back the timeline for the possible approval of AXS-05 and its other candidates.

This has created a great buy opportunity for investors as the long-term narrative hasn't changed. Although anything can happen in the world of biotechnology and disappointments occur frequently, Axsome's lead candidate appears to be on a solid path to eventually earn its breakthrough tag.

It seems that market impatience has contributed to this stock's $40 swoon since the April breakout. Perhaps some traders didn't want to wait around for the big news. But those that do hang on could get their high risk reward later this year—and see Axsome's share price head back to triple digit territory quickly.

Ten of the 11 sell-side analyst that cover Axsome call it a 'buy'. All price targets for the stock are north of $100 and one firm, H.C. Wainright sees the $68 stock heading above $200.

Axsome has a potential blockbuster drug on its hands in AXS-05 which could soon hit the market as a treatment for several indications. Positive late-stage data may soon translate to some much-needed treatment for CNS disorder patients, billion in revenue for Axsome, and major gains for Axsome shareholders.

7 Entertainment Stocks That Are Still Delighting Investors

2020 has created a real-life movie script that many production companies could have only dreamed of. But that dream has been a nightmare for many of the world’s leading entertainment stocks. Movie theaters and live entertainment venues remain shut down. The words “pent-up demand” have never resonated more. Consumers are desperate for ways to be entertained.

That may make it an odd time to consider looking at entertainment stocks. But that would be a mistake. In fact, some entertainment stocks have been among the biggest pandemic winners. This is a trend that is likely to continue as the holidays arrive. The phrase “home for the holidays” is likely to have a new meaning this year. That means consumers will still be looking for ways to be entertained. And now is the time for you to prepare your portfolio for that move.

To be clear, the novel coronavirus was not due to poor management from any company. And you can bet that in the future, many companies will leave some room in their balance sheet for future “acts of God.” But in the meantime, some entertainment stocks have been pandemic winners. And that means they will likely continue to be winners as long as the pandemic lingers.

View the "7 Entertainment Stocks That Are Still Delighting Investors".

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Axsome Therapeutics (AXSM)1.4$52.99flatN/A-19.70Buy$146.90
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.